NeuroPace (NPCE) said Monday that Medicare reimbursement will "substantially increase" for its RNS neurostimulator implant and replacement procedures.
The physician fee schedule for 2026 increases professional payment for neurosurgeons by about 43% for the initial implant and 45% for replacement procedures, the company said.
Separately, the outpatient prospective payment system final rule increases average hospital medicare reimbursement by 47% starting Jan. 1, 2026.
Shares of NeuroPace were up by 2% in recent Monday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments